Generic Maker Sues FDA Over VOQUEZNA's GAIN Act Exclusivity Extension
Company Background
Phathom Pharmaceuticals markets a single commercial product: VOQUEZNA (vonoprazan fumarate), a potassium-competitive acid blocker approved for erosive and non-erosive GERD and H. pylori infection. The drug was in-licensed from Takeda for the U.S., Europe, and Canada. Revenue has scaled sharply since launch — from $55.3 million in 2024 to $175.1 million in 2025 — and accelerated further into 2026, with Q2 net revenues of $74.3 million representing an 88% year-over-year increase and the first instance of non-GAAP operating profitability, excluding stock-based compensation.
The improving commercial trajectory has not yet translated into a clean balance sheet. Total liabilities stood at $671 million against $327 million in total assets as of June 30, 2026, leaving a stockholders' deficit of $344 million. The company carries both term debt and a revenue interest financing agreement (RIFA) that includes cash hold covenants beginning in October 2026; management has said the highest cash hold obligation during 2026 is expected to reach approximately $120 million. Cash on hand at June 30, 2026 was $182.5 million.
In January 2026, Phathom raised approximately $130 million in a public offering of common stock and pre-funded warrants, then used a portion of the proceeds to reduce and refinance its term debt. Management has since stated it does not anticipate needing additional equity financing, citing anticipated cash generation from VOQUEZNA operations. Full-year 2026 revenue guidance, revised in July from $320–345 million to $310–325 million, is based entirely on VOQUEZNA sales.
What Was Disclosed
BDR Pharmaceuticals International Pvt. Ltd. filed suit against the FDA and related federal defendants on October 23, 2026, in the U.S. District Court for the District of Columbia. The suit challenges FDA's alleged refusal to receive an abbreviated new drug application — the regulatory pathway for generic drugs — referencing Phathom's NDA for VOQUEZNA. BDR's central argument is that the FDA improperly applied the Generating Antibiotic Incentives Now Act, known as the GAIN Act, to grant Phathom's NCE exclusivity extension.